Although substantial progress has been made in the prevention and treatment of cardiovascular disease and its major risk factors, it has been predicted that thrombotic complications will remain the leading cause of death and disability and will represent a major burden to productivity worldwide well into the year 2020. Thrombosis remains the most prevalent cause of fatal diseases in developed countries. More than 80% of stroke cases are of thrombotic origin, and stroke is among the three leading causes of mortality and severe chronic disability in the US. Systemic anticoagulants like heparin prevent co-morbidity from deep vein thrombosis and reduce the progression of acute cerebral thrombosis. However, their bleeding side effects in the acute phase outweigh the benefits. An antithrombotic agent that can be administered to patients with severe acute thrombotic diseases, such as heart attack and stroke, without the risk of causing hemorrhage, would revolutionize the treatment of cardiovascular and cerebrovascular diseases. Protein engineering of thrombin has led to the development of the mutant W215A/E217A (WE) that is capable of sustained anticoagulant effects in non-human primates without bleeding complications. WE has compromised activity toward fibrinogen and PARI, but retains activity toward the anticoagulant protein C. Activation of protein C by WE on the endothelium is more effective in producing an anticoagulant effect than systemic administration of activated protein C. In addition to exploiting the protein C anticoagulant pathway, WE is capable of producing a profound antiplatelet effect by engaging the Gplb receptor and preventing its interaction with von Willebrand factor, which is a property not present in either activated protein C or heparin. Filing of an IND for the mutant WE is on track for August 2012. The remarkable success of WE in pre-clinical studies and its extraordinary promise as an effective anticoagulant/antithrombotic may be compromised in humans by its residual activity toward fibrinogen and PARI. The goal of this research project is to produce a new generation of thrombin mutants that have completely lost their activity toward fibrinogen and PARI, but retain activity toward protein C in the presence of the cofactor thrombomodulin.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HL112303-02
Application #
8464255
Study Section
Special Emphasis Panel (ZHL1-CSR-C)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$251,649
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Barranco-Medina, Sergio; Murphy, Mary; Pelc, Leslie et al. (2017) Rational Design of Protein C Activators. Sci Rep 7:44596
Shen, Guomin; Cui, Weidong; Zhang, Hao et al. (2017) Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. Nat Struct Mol Biol 24:69-76
Chakraborty, Pradipta; Di Cera, Enrico (2017) Induced Fit Is a Special Case of Conformational Selection. Biochemistry 56:2853-2859
Sadler, J Evan (2017) Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130:1181-1188
Liszewski, M Kathryn; Java, Anuja; Schramm, Elizabeth C et al. (2017) Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol 12:25-52
Vedantham, Suresh; Goldhaber, Samuel Z; Julian, Jim A et al. (2017) Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med 377:2240-2252
Lokki, A Inkeri; Daly, Emma; Triebwasser, Michael et al. (2017) Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population. Hypertension 70:365-371
Sanfilippo, K M; Wang, T F; Gage, B F et al. (2016) Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res 143:86-90
Wagner, Erin K; Raychaudhuri, Soumya; Villalonga, Mercedes B et al. (2016) Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Sci Rep 6:31531
Gillrie, Mark R; Renaux, Bernard; Russell-Goldman, Eleanor et al. (2016) Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence. MBio 7:

Showing the most recent 10 out of 81 publications